Verastem is a biotechnology business based in the US. Verastem shares (VSTM) are listed on the NASDAQ and all prices are listed in US Dollars. Verastem employs 73 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.97 |
|---|---|
| 52-week range | $2.60 - $14.22 |
| 50-day moving average | $5.45 |
| 200-day moving average | $8.56 |
| Wall St. target price | $22.21 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-4.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.97 from 2024-07-25
| 1 week (2024-07-19) | -10.54% |
|---|---|
| 1 month (2024-06-27) | 2.41% |
| 3 months (2024-04-26) | -68.34% |
| 6 months (2024-01-26) | -74.22% |
| 1 year (2023-07-27) | -69.19% |
|---|---|
| 2 years (2022-07-27) | 162.83% |
| 3 years (2021-07-27) | 3.27 |
| 5 years (2019-07-26) | 102.04% |
| Gross profit TTM | $2.6 million |
|---|---|
| Return on assets TTM | -51.55% |
| Return on equity TTM | -210.18% |
| Profit margin | 0% |
| Book value | $0.99 |
| Market Capitalization | $84.1 million |
TTM: trailing 12 months
We're not expecting Verastem to pay a dividend over the next 12 months.
Verastem's shares were split on a 1:12 basis on 31 May 2023. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Verastem shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Verastem shares which in turn could have impacted Verastem's share price.
Over the last 12 months, Verastem's shares have ranged in value from as little as $2.6 up to $14.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verastem's is 0.187. This would suggest that Verastem's shares are less volatile than average (for this exchange).
Verastem, Inc. , a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co. , Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.